Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

parathyroid hormone

Novartis building

Novartis’ Ilaris cleared for gouty arthritis in EU

First biologic drug approved for condition in Europe

- PMLiVE

Novartis provides multimedia support to Rare Diseases Day

Collaborates with Eurordis on multimedia education campaign

Novartis to expand SMS for Life approach across Africa

Will broaden reach of mobile-based medicines management programme 

- PMLiVE

Novartis gives Vasella honorary role as payout row continues

Named honorary chairman chairman at Swiss pharma firm after stepping down as chairman

- PMLiVE

CHMP upholds rejection of Vivus’ obesity drug

Still no recommendation for Qsiva in Europe

- PMLiVE

Gentium expects EMA rejection for defibrotide

Negative feedback for drug’s use in liver condition associated with stem cell transplantation

- PMLiVE

Novartis, Roche under scrutiny in Italy on Avastin/Lucentis collusion claims

Antitrust authorities in Italy open investigation into the pharma companies

- PMLiVE

BMS hires Shire’s Ann Powell Judge to head human resources

She has also served at Wyeth and the Dow Chemical Company

Novartis building

Novartis’ Zortress cleared by FDA for liver transplants

Adds to kidney transplant indication in the US

- PMLiVE

Shire weathers generic Adderall XR challenge

Fourth quarter revenues rise 5 per cent to $1.1bn

Novartis building

Novartis’ Jakavi turned down by NICE for blood cancer

UK cost-effectiveness watchdog concerned about 'uncertainties' in data in draft guidance

- PMLiVE

Shire pays $48m to settle generic Adderall XR claims with Impax

Avoids court battle over supply issues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links